allogeneic CD8+ T-lymphocyte therapy (Tevogen Bio)

N/A

Report date: 2025/01/26 18:22:17

Base Information

Drug Nameallogeneic CD8+ T-lymphocyte therapy (Tevogen Bio)
Drug Alias Nameallogeneic TCR T-cell therapy (Tevogen Bio)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTevogen Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTevogen Bio Inc
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A